Perceptive Advisors
Perceptive Advisors LLC is an investment management firm founded in 1999 and headquartered in New York City, with an additional office in Boston. The firm specializes in the healthcare sector, focusing on biotechnology, pharmaceuticals, life sciences, diagnostics, digital health, medical devices, and healthcare services. It engages in venture capital and incubation, investing at various stages of a company's life cycle, including seed and Series A funding, as well as late-stage venture and public market investments. Perceptive Advisors employs a long/short equity strategy and utilizes hedging techniques, including equity options and index options, while conducting in-house research to inform investment decisions. The firm also manages separate client-focused equity portfolios and provides customized debt financing solutions through its Perceptive Credit Opportunities Fund. Its clientele includes institutional investors, financial institutions, investment funds, and high-net-worth individuals.
Silagene is a biotech company developing technology designed to facilitate the creation of U1 adaptors with therapeutic potential. The company's technology overcomes the limitations of gene silencing technologies, enabling doctors to to treat patients with various types of cancers.
It was founded in 2008 and is based in Hillsborough, New Jersey, United States.
Impulse Dynamics N.V. is a medical device company focused on developing electrical therapies for chronic heart failure (CHF) in the United States and Europe. The company specializes in Cardiac Contractility Modulation therapy, utilizing its proprietary technology to administer non-excitatory electrical impulses that enhance cardiac performance. The Optimizer III device, which is CE marked, delivers these impulses to the ventricular septum during the myocardial absolute refractory period. Impulse Dynamics conducts clinical trials to evaluate the safety and efficacy of its treatments and collaborates with universities and hospitals for research programs. Founded in 1996 and headquartered in Willemstad, Curacao, the company also has offices in New York and Hong Kong, along with product development centers in New Jersey and Israel.
Agile Therapeutics, Inc., a specialty pharmaceutical company, engages in the development of women's healthcare products. It offers a low estrogen dose seven-day transdermal contraceptive patch system that delivers a combination of levonorgestrel and Ethinylestradiol.
The company was founded in 1997 as Levotech, Inc. and changed its name to Agile Therapeutics, Inc. in April 2001. It is based in Princeton, New Jersey.
Clover Health is a health insurance company that provides Medicare Advantage plans primarily for senior citizens in New Jersey, and it also serves members in several other states, including Arizona, Georgia, Pennsylvania, South Carolina, Tennessee, and Texas. Founded in 2014 and based in San Francisco, Clover Health operates a Preferred Provider Organization (PPO) platform aimed at enhancing the quality of life for its members. The company focuses on preventive care through patient-centered analytics and a dedicated care management team, which helps identify potential health risks and manage chronic diseases. By employing advanced analytics and custom software, Clover Health directs its clinical staff to address care gaps, ultimately aiming to reduce unnecessary healthcare costs while improving health outcomes for its members.
Foamix Pharmaceuticals Inc. a pharmaceutical company, engages in development and commercialization of proprietary, innovative, and differentiated topical drugs for dermatological conditions. It offers Molecule Stabilizing Technology (MST) platform. The company was incorporated in 2014 and is based in Bridgewater, New Jersey. Foamix Pharmaceuticals Inc. operates as a subsidiary of Menlo Therapeutics Inc.
ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics aimed at treating immune deficiencies and infectious diseases in the United States. The company's product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin products indicated for primary humoral immunodeficiency, as well as Nabi-HB, which treats acute exposure to Hepatitis B. ADMA also has a pipeline of therapeutics targeting infections such as S. pneumonia. To support its production, ADMA operates FDA-licensed source plasma collection facilities, known as ADMA BioCenters, which supply plasma for its products. The company distributes its offerings through independent distributors, sales agents, and specialty pharmacies. Founded in 2004 and headquartered in Ramsey, New Jersey, ADMA Biologics is dedicated to serving niche patient populations, particularly those who are immune-compromised due to underlying conditions or medical treatments.
Vyome Therapeutics focuses on developing innovative treatments for antibiotic-resistant acne and other pathogens through a unique pipeline of antibiotics designed to slow the development of resistance. The company's product portfolio includes VB 1953, its lead molecule targeting the significant unmet needs in the resistant acne market, along with various anti-dandruff products such as VB 001 (a leave-on scalp care treatment), VB 2421 (a hair gel), VB 3222 (a wash-off shampoo), and VB 7731 (a Ketoconazole emulsion gel). Established in 2010 and based in Princeton, New Jersey, the company incorporates advanced research and development capabilities, including formulation, analytical, and clinical divisions. Vyome's management team boasts extensive expertise in dermatology and has a proven track record of successfully launching numerous products. The firm is committed to addressing refractory skin conditions and aims to bring its innovative therapies to market effectively.
Vyome Therapeutics focuses on developing innovative treatments for antibiotic-resistant acne and other pathogens through a unique pipeline of antibiotics designed to slow the development of resistance. The company's product portfolio includes VB 1953, its lead molecule targeting the significant unmet needs in the resistant acne market, along with various anti-dandruff products such as VB 001 (a leave-on scalp care treatment), VB 2421 (a hair gel), VB 3222 (a wash-off shampoo), and VB 7731 (a Ketoconazole emulsion gel). Established in 2010 and based in Princeton, New Jersey, the company incorporates advanced research and development capabilities, including formulation, analytical, and clinical divisions. Vyome's management team boasts extensive expertise in dermatology and has a proven track record of successfully launching numerous products. The firm is committed to addressing refractory skin conditions and aims to bring its innovative therapies to market effectively.
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative medicines to meet unmet medical needs both in the United States and internationally. The company offers several marketed products, including Sympazan, an oral soluble film for treating Lennox-Gastaut syndrome; Suboxone, a sublingual film for opioid dependence; and Zuplenz, an oral soluble film for nausea and vomiting related to chemotherapy and post-operative recovery. Additionally, Aquestive's proprietary product candidates include Libervant, a buccal film for epileptic seizures, and Exservan, an oral film for Amyotrophic Lateral Sclerosis. The company's pipeline also features AQST-108, a sublingual film for anaphylaxis, AQST-305 for acromegaly, and APL-130277 for Parkinson's disease. Established in 2004 and headquartered in Warren, New Jersey, Aquestive Therapeutics leverages its proprietary technologies to address complex healthcare challenges and partners with other pharmaceutical companies to enhance drug delivery methods.
Arno Therapeutics is a biopharmaceutical company focused on creating value through the development of innovative products for the treatment of cancer patients.
Arno Therapeutics is a biopharmaceutical company focused on creating value through the development of innovative products for the treatment of cancer patients.
Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics. It is advancing its pipeline of 11 biosimilar products, two of which are currently in clinical development. The company employs its BioSymphony biosimilars business model to achieve accelerated development and technical excellence in order to create affordable medicines for patients around the world.
Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics. It is advancing its pipeline of 11 biosimilar products, two of which are currently in clinical development. The company employs its BioSymphony biosimilars business model to achieve accelerated development and technical excellence in order to create affordable medicines for patients around the world.
Champions Oncology, Inc. specializes in developing technology solutions and products aimed at personalizing the treatment of cancer. The company employs its Tumorgraft Technology Platform, which involves implanting human tumors in immune-deficient mice, to provide Personalized Oncology Solutions (POS). This platform enables physicians to tailor treatment options based on specific tumor data obtained from drug panels. Additionally, Champions Oncology offers Translational Oncology Solutions to assist pharmaceutical and biotechnology companies in their drug development processes. The company's product offerings include TumorGraft implants and drug panels that evaluate the response of a patient's tumor to various oncology drugs or combinations. Champions Oncology markets its products through online channels, referrals, and a dedicated sales team. Founded by leading experts in cancer research and treatment, the company is headquartered in Hackensack, New Jersey, and was incorporated in 1985.
Arno Therapeutics is a biopharmaceutical company focused on creating value through the development of innovative products for the treatment of cancer patients.